QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook
Q1 2025 preliminary net sales rise 7% CER and adjusted diluted EPS results of at least $0.55 CER both above outlook despite challenging macro environment
Full-year 2025 adjusted diluted EPS outlook raised to about $2.35 CER (prior outlook about $2.28 CER)
On track to exceed 31% CER adjusted operating income margin ahead of 2028 mid-term target
VENLO, Netherlands, April 06, 2025--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary Q1 2025 results that exceeded its outlook for both net sales and adjusted earnings per share (EPS), reflecting strong performances across many growth drivers.
Net sales grew approximately 5% (+7% at constant exchange rates, CER) to about $483 million in Q1 2025, surpassing the previously communicated outlook for about 3% CER growth (4% CER core business excluding discontinued products such as NeuMoDx and Dialunox). Adjusted diluted EPS are expected to be at least $0.55 CER compared to the previously communicated outlook for about $0.50 CER.
Sales of the QuantiFERON latent TB test grew about 15% CER as global adoption continues to shift from the skin test to this proven, modern blood-based test. The QIAstat-Dx syndromic testing system advanced above 35% CER on continued demand for respiratory panels along with growth in gastrointestinal and meningitis testing. The QIAcuity digital PCR system and QIAGEN Digital Insights bioinformatics business both delivered high-single-digit CER gains, reflecting solid adoption across research and clinical applications. Additional growth contributions also came from higher sales of PCR consumables and from OEM products. Sample technologies sales declined 1% CER, reflecting the cautious instrument spending environment among some Life Sciences customers.
Given the positive start to 2025, QIAGEN is raising its adjusted diluted EPS outlook for full-year 2025 in light of the strong sales growth in Q1 and the overall current business trends, which includes expected headwinds from the recently announced U.S. import tariffs and a better-than-expected tax environment.
Full-year 2025, adjusted diluted EPS are now expected to be about $2.35 CER, up from the prior full-year outlook for about $2.28 CER, while reaffirming the goal to improve the adjusted operating income margin to above 30% for the year.
QIAGEN will provide additional perspectives on the outlook for full-year 2025 with the publication of full Q1 2025 results on May 7, 2025.
Additionally, QIAGEN now expects to reach the mid-term adjusted operating income margin goal of at least 31% well ahead of the original 2028 timeline, reflecting the stronger-than-anticipated improvements delivered during 2024 and 2025.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of December 31, 2024, QIAGEN employed more than 5,700 people in over 35 locations worldwide. For more information, visit www.qiagen.com.
Forward-Looking StatementCertain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's financial and operational outlook, including its expected Q1 25 and full year net sales, adjusted diluted EPS and adjusted operating income margin, products, development timelines, marketing and / or regulatory approvals, growth strategies, collaborations and operating results are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, tariffs, regulatory processes and logistical dependencies), variability in operating results and allocations between customer classes, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated financial and operational results will materialize as expected. For a comprehensive overview of risks, please refer to the "Risk Factors" contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission.
Source: QIAGENCategory: Corporate
View source version on businesswire.com: https://www.businesswire.com/news/home/20250406144830/en/
Contacts
Contacts QIAGEN: Investor Relations John Gilardi, +49 2103 29 11711Domenica Martorana, +49 2103 29 11244e-mail: ir@QIAGEN.com
Public Relations Thomas Theuringer, +49 2103 29 11826e-mail: pr@QIAGEN.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Park Aerospace Corp. Declares Cash Dividend
NEWTON, Kan., June 09, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Park Aerospace Corp. (NYSE-PKE) has declared a regular quarterly cash dividend of $0.125 per share payable August 1, 2025 to shareholders of record at the close of business on July 1, 2025. Park has paid 40 consecutive years of uninterrupted regular quarterly cash dividends, without ever skipping a dividend payment or reducing the amount of the dividend. The Company has paid $603.6 million in cash dividends, or $29.475 per share, since the beginning of the Company's 2005 fiscal year. Park Aerospace Corp. develops and manufactures solution and hot-melt advanced composite materials used to produce composite structures for the global aerospace markets. Park's advanced composite materials include film adhesives (Aeroadhere®) and lightning strike protection materials (Electroglide®). Park offers an array of composite materials specifically designed for hand lay-up or automated fiber placement (AFP) manufacturing applications. Park's advanced composite materials are used to produce primary and secondary structures for jet engines, large and regional transport aircraft, military aircraft, Unmanned Aerial Vehicles (UAVs commonly referred to as 'drones'), business jets, general aviation aircraft and rotary wing aircraft. Park also offers specialty ablative materials for rocket motors and nozzles and specially designed materials for radome applications. As a complement to Park's advanced composite materials offering, Park designs and fabricates composite parts, structures and assemblies and low volume tooling for the aerospace industry. Target markets for Park's composite parts and structures (which include Park's proprietary composite SigmaStrut™ and AlphaStrut™ product lines) are, among others, prototype and development aircraft, special mission aircraft, spares for legacy military and civilian aircraft and exotic spacecraft. Park's objective is to do what others are either unwilling or unable to do. When nobody else wants to do it because it is too difficult, too small or too annoying, sign us up. Additional corporate information is available on the Company's website at Contact: Donna D'Amico-Annitto 486 North Oliver Road, Bldg. ZNewton, Kansas 67114(316) 283-6500Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
KSTM Promotes Eric Saar to Partner
Saar Brings KSTM Matrimonial and Family Law Practice to Clients in New Jersey NEW YORK, June 09, 2025--(BUSINESS WIRE)--Krauss Shaknes Tallentire & Messeri LLP announced today that Eric Saar, a skilled litigator newly licensed to practice in New Jersey, has been promoted to partner. "Eric has a wealth of expertise in matrimonial and family law, and his talent as a negotiator, writer, and litigator make him a valuable asset to his clients and colleagues at our firm," said KSTM founding partner Caroline Krauss. "Now barred in New Jersey as well as New York, he has expanded the reach of his practice and allowed KSTM to serve clients in New Jersey seamlessly." Saar's experience in matrimonial and family law matters includes the division of complex assets, highly intricate custody matters, spousal and child support issues, and the preparation and negotiation of pre- and post-nuptial agreements. He is an active member of the New York City Bar Association's Matrimonial Law Committee and previously served as co-chair of the Legislative Affairs subcommittee. Saar is also a member of the New York State Bar Association's Family Law Section. Saar will play a key role as KSTM expands its presence and capabilities in New Jersey. His recent admission to the New Jersey Bar allows the firm to practice in the state without the need for local co-counsel. "I am honored to join KSTM's partnership and to play a role in expanding the firm's presence into New Jersey," said Saar. "I look forward to bringing our empathetic, client-focused approach to individuals and families throughout the state, and to continuing to guide our clients through some of life's most challenging moments with clarity, compassion, and an unwavering commitment to their goals." Saar's professional honors include being named a New York Super Lawyer in Family Law (2024-25) and Rising Star in Family Law (2020-23), and a Best Lawyers' One to Watch for Family Law in New York (2024). Before joining KSTM, Saar was an associate at Greenspoon Marder LLP. He has focused on matrimonial law since prior to his graduation from the University of Illinois Chicago John Marshall Law School, serving as a law clerk for the largest law firm in the country that practices matrimonial law exclusively. About Krauss Shaknes Tallentire & Messeri LLP Krauss Shaknes Tallentire & Messeri LLP ( provides counsel to clients in the full range of matrimonial and family law matters, including pre- and post-nuptial agreements, divorces, paternity matters, custody, access, and support issues, and other family law matters. We have offices in New York City, New Jersey, and Greenwich, Connecticut. View source version on Contacts Kelsey Dellovokdellovo@ 339.223.0961 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Trevor Schulze Joins Genesys as Chief Information Officer
SAN FRANCISCO, June 09, 2025--(BUSINESS WIRE)--Genesys®, a global cloud leader in AI-Powered Experience Orchestration, today announced the appointment of Trevor Schulze as Chief Information Officer (CIO). Schulze will oversee the Genesys global information technology organization to further advance the company's AI and cloud strategy and support its continued growth. "Trevor is a transformational leader with a proven track record of driving enterprise innovation at scale," said Tony Bates, Chairman and CEO of Genesys. "His deep expertise in AI, cloud and customer-centric digital transformation will help us accelerate our vision of delivering the power of empathy to every customer experience." Schulze brings more than 30 years of experience driving business success through innovative technology solutions. Schulze joins Genesys from Alteryx, where he was most recently the senior vice president and Chief Digital and Information Officer, responsible for leading the company's digital transformation and enterprise AI initiatives. Prior to Alteryx, Schulze held CIO and senior leadership roles at RingCentral and Micron Technology, where he led strategic initiatives across enterprise AI, customer experience and cloud modernization. He has also held senior information technology positions at Broadcom Corporation, Advanced Micro Devices and Cisco Systems. "Genesys is redefining what is possible at the intersection of AI and customer experience orchestration," said Schulze. "The pace of innovation here is reshaping how technology can deliver powerful outcomes to organizations—with agentic AI emerging as a true differentiator. As we pioneer the next wave of customer experience transformation, my focus will be on strengthening our foundation to unlock new levels of value for our customers." About Genesys Genesys empowers more than 8,000 organizations in over 100 countries to improve loyalty and business outcomes by creating the best experiences for their customers and employees. Through Genesys Cloud, the AI-Powered Experience Orchestration platform, Genesys delivers the future of CX to organizations of all sizes so they can provide empathetic, personalized experience at scale. As the trusted platform that is born in the cloud, Genesys Cloud helps organizations accelerate growth by enabling them to differentiate with the right customer experience at the right time, while driving stronger workforce engagement, efficiency and operational improvements. Visit View source version on Contacts Janelle Dickerson Method Communications Genesys@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data